What is Illumina?
Illumina Inc (ILMN) is a San Diego-based U.S. company engaged in the development and marketing of genetic analysis solutions and life science services. Over the past decade it has become a global leader in genomics. Illumina offers a broad portfolio of instruments including NovaSeq Sequencing Systems,HiSeq Sequencing Systems, HiScan Array Scanner and others.
Illumina explains that its aim is “to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago”. The company says it delivers innovative, flexible, and scalable solutions to meet the needs of its customers.These customers include leading genome research centres and a variety of other academic, governmental, pharmaceutical and biotechnology institutions around the world.
In 2017 Forbes ranked Illumina no.18 in its annual list of the world’s most innovative companies. The company was also ranked no.34 in its league table of America's best midsize employers, and no.175 in Forbes’ list of growth champions. As of 6 April 2018, Illumina Inc had a market capitalisation of some $34.14 billion.
Who are the key people at Illumina?
Francis de Souza, who has been President & CEO of Illumina Inc since 2016, is responsible for directing all aspects of company strategy, planning and operations. Other key figures at the company include: Garret Hampton (Executive Vice President, Clinical Genomics); Omead Ostadan (Executive Vice President, Products & Operations); and Marc Stapley (Executive Vice President, Strategy & Corporate Development).
What is the modern history of Illumina?
The company was foundedin 1998 by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee. It acquired Spyder Instruments the following year, and completed its initial public offering in 2000. The acquisition of Solexa Inc followed in 2007, and Epicentre Biotechnologies was acquired in 2011. Roche made an unsolicited bid to buy Illumina for around $5.7 billion in 2012, but both this and a subsequent higher offer were rejected. In 2015, Illumina spun off the blood testing company Grail.
What are the latest developments at Illumina?
In its financial results for fiscal year 2017, Illumnia Inc reported revenue of $2.75 billion, a 15% increase from $2.40 billion in fiscal year 2016.GAAP net income attributable to Illumina stockholders was $726 million, or $4.92 per diluted share, against $463 million or $3.07 per diluted share in 2016.For fiscal year 2018, the company forecast 13-14% revenue growth, and GAAP earnings per diluted share attributable to Illumina stockholders of $4.14-$4.24.
Long-term investors in Illumina saw the value of their holdings increase significantly between 2013 and 2018. From $54 in January 2013, the Illumina share price climbed to $100 in December 2013, $150 in February 2014, and $200 in May 2015. The shares slipped in the second half of 2015, but by March 2018 the stock had recovered to a new high of $253. To find out how the shares are doing right now, follow Capital.com. Our ILMN chart puts all the information at your fingertips.
Where does Illumina operate?
Headquartered in San Diego, California,Illumina's regional subdivisions operate in the United States, Brazil, the United Kingdom, the Netherlands, Singapore, China, Japan and Australia.The company employs over 5,500 people.
Where is Illumina traded?
The company shares are traded on the NASDAQ stock exchange and are constituents of the S&P 500 index. Check out Capital.com for the latest ILMN chart. We’ll keep you up to date and in the picture.
